<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892017</url>
  </required_header>
  <id_info>
    <org_study_id>DCC-3116-01-001</org_study_id>
    <nct_id>NCT04892017</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.</brief_title>
  <official_title>A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination With Trametinib in Patients With Advanced or Metastatic Solid Tumors With RAS or RAF Mutations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deciphera Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deciphera Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, multicenter, open-label, first-in-human (FIH) study designed to evaluate&#xD;
      the safety, tolerability, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD)&#xD;
      of DCC-3116 as a single agent and in combination with trametinib in patients with advanced or&#xD;
      metastatic solid tumors with RAS or RAF mutations. The study consists of 2 parts, a&#xD;
      dose-escalation phase, and an expansion phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Identify the observed adverse events, serious adverse events associated with DCC-3116</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Approximately 18 months</time_frame>
    <description>Identify the dose-limiting toxicities for each dose level tested and determine the maximum tolerated dose and recommended Phase 2 dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) (Expansion Phase)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Proportion of participants who achieve CR or PR per RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR) (Escalation Phase)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>DoR is defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that the progressive disease is objectively documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR) (Escalation Phase)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>The proportion of participants who achieve CR, PR, or SD per RECIST v1.1 at the corresponding assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (Escalation Phase)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Time to response is defined as the time from initiation of treatment until the first assessment demonstrating CR or PR per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) (Escalation Phase)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>PFS is defined as the time from initiation of treatment until documented disease progression per RECIST v1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Predose and up to 12 hours postdose.</time_frame>
    <description>Measure the maximum observed concentration of DCC-3116 (single-agent and combination)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed concentration (Tmax)</measure>
    <time_frame>Predose and up to 12 hours postdose.</time_frame>
    <description>Measure the time to maximum plasma concentration of DCC-3116 (single-agent and combination)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed concentration (Cmin)</measure>
    <time_frame>Predose and up to 12 hours postdose.</time_frame>
    <description>Measure the minimum observed concentration of DCC-3116 (single-agent and combination)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve( AUC)</measure>
    <time_frame>Predose and up to 12 hours postdose.</time_frame>
    <description>Measure the AUC of DCC-3116 (single-agent and combination)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Advanced Solid Tumor</condition>
  <condition>Metastatic Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Dose Escalation (Part 1-A Monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCC-3116 tablets in escalating dose cohorts given orally twice daily (BID) in 28-day cycles as monotherapy (single agent). If no DLT in 3 participants or 1 DLT/6 participants is observed, dose escalation will continue to the next planned dose cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation (Part 1-B Combination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with trametinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 1 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCC-3116 tablets BID given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with pancreatic ductal adenocarcinoma (PDAC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 2 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCC-3116 tablets orally BID given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with non-small cell lung cancer (NSCLC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 3 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCC-3116 tablets orally BID given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with colorectal cancer (CRC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 4 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCC-3116 tablets orally BID given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with melanoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCC-3116</intervention_name>
    <description>Oral Tablet Formulation</description>
    <arm_group_label>Dose Escalation (Part 1-A Monotherapy)</arm_group_label>
    <arm_group_label>Dose Escalation (Part 1-B Combination)</arm_group_label>
    <arm_group_label>Expansion Cohort 1 (Part 2)</arm_group_label>
    <arm_group_label>Expansion Cohort 2 (Part 2)</arm_group_label>
    <arm_group_label>Expansion Cohort 3 (Part 2)</arm_group_label>
    <arm_group_label>Expansion Cohort 4 (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Oral Tablet Formulation</description>
    <arm_group_label>Dose Escalation (Part 1-B Combination)</arm_group_label>
    <arm_group_label>Expansion Cohort 1 (Part 2)</arm_group_label>
    <arm_group_label>Expansion Cohort 2 (Part 2)</arm_group_label>
    <arm_group_label>Expansion Cohort 3 (Part 2)</arm_group_label>
    <arm_group_label>Expansion Cohort 4 (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female participants â‰¥18 years of age at the time of informed consent.&#xD;
&#xD;
          2. Dose Escalation Phase:&#xD;
&#xD;
               1. Participants must have a histologically confirmed diagnosis of an advanced or&#xD;
                  metastatic solid tumor with a documented RAS or RAF mutation.&#xD;
&#xD;
               2. Progressed despite standard therapies, and received at least 1 prior line of&#xD;
                  anticancer therapy.&#xD;
&#xD;
                    -  Participants with a documented mutation in BRAF V600E or V600K must have&#xD;
                       received approved treatments known to provide clinical benefit prior to&#xD;
                       study entry.&#xD;
&#xD;
          3. Dose Expansion Phase:&#xD;
&#xD;
               1. Cohort 1: Pancreatic Ductal Adenocarcinoma.&#xD;
&#xD;
                    -  Histologically confirmed PDAC with a documented mutation in KRAS or BRAF.&#xD;
&#xD;
                    -  Received at least 1 prior line but no more than 3 prior lines of systemic&#xD;
                       therapy in the advanced or metastatic setting.&#xD;
&#xD;
               2. Cohort 2: Non-Small Cell Lung Cancer&#xD;
&#xD;
                    -  Histologically confirmed NSCLC with a documented mutation in KRAS, NRAS, or&#xD;
                       BRAF.&#xD;
&#xD;
                    -  Received at least 2 prior lines but no more than 4 prior lines of systemic&#xD;
                       therapy in the advanced or metastatic setting.&#xD;
&#xD;
               3. Cohort 3: Colorectal Cancer&#xD;
&#xD;
                    -  Histologically confirmed CRC with a documented mutation in KRAS, NRAS, or&#xD;
                       BRAF.&#xD;
&#xD;
                    -  Received at least 2 prior lines of systemic therapy in the advanced or&#xD;
                       metastatic setting.&#xD;
&#xD;
               4. Cohort 4: Melanoma&#xD;
&#xD;
                    -  Histologically confirmed melanoma with a documented mutation in NRAS or&#xD;
                       BRAF.&#xD;
&#xD;
                    -  Received at least 2 prior lines but no more than 4 prior lines of systemic&#xD;
                       therapy in the advanced or metastatic setting.&#xD;
&#xD;
          4. Must be able to provide tumor tissue sample&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 at Screening&#xD;
&#xD;
          6. Adequate organ function and bone marrow function.&#xD;
&#xD;
          7. If a female of childbearing potential must have a negative pregnancy test prior to&#xD;
             enrollment and agree to follow the contraception requirements.&#xD;
&#xD;
          8. Male participants must agree to follow contraception requirements.&#xD;
&#xD;
          9. Must provide signed consent to participate in the study and is willing to comply with&#xD;
             study-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received prior anticancer therapy, including investigational therapy within 2 weeks or&#xD;
             5 Ã— the half-life (whichever is shorter) prior to the first dose of study drug.&#xD;
&#xD;
          2. Have not recovered from all toxicities from prior therapy according to National Cancer&#xD;
             Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).&#xD;
&#xD;
          3. Symptomatic central nervous system (CNS) metastases or presence of leptomeningeal&#xD;
             disease Note: A participant with previously treated brain metastases may participate&#xD;
             provided that they are stable.&#xD;
&#xD;
          4. New York Heart Association Class III or IV heart disease, active ischemia, or any&#xD;
             other uncontrolled cardiac condition such as angina pectoris, clinically significant&#xD;
             cardiac arrhythmia requiring therapy, uncontrolled hypertension, congestive heart&#xD;
             failure, or myocardial infarction within 6 months prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
          5. Prolongation of the QT interval corrected by Fridericia's formula (QTcF) based on&#xD;
             repeated demonstration of QTcF &gt;450 ms in males or &gt;470 ms in females at screening, or&#xD;
             history of long QT syndrome.&#xD;
&#xD;
          6. Left ventricular ejection fraction (LVEF) &lt;50% at Screening&#xD;
&#xD;
          7. Systemic arterial thrombotic or embolic events&#xD;
&#xD;
          8. Systemic venous thrombotic events&#xD;
&#xD;
          9. A history or current evidence/risk of retinal vein occlusion (RVO) or central serous&#xD;
             retinopathy including uncontrolled glaucoma or ocular hypertension, uncontrolled&#xD;
             hypertension, uncontrolled diabetes mellitus, or a history of hyperviscosity or&#xD;
             hypercoagulability syndromes.&#xD;
&#xD;
         10. Concurrent neuromuscular disorder that is associated with the potential of elevated&#xD;
             creatine kinase.&#xD;
&#xD;
         11. Bone disease that requires treatment.&#xD;
&#xD;
         12. Major surgery within 4 weeks of the first dose of study drug. All surgical wounds must&#xD;
             be healed and free of infection or dehiscence before the first dose of the study drug.&#xD;
&#xD;
         13. Any other clinically significant comorbidities.&#xD;
&#xD;
         14. For participants receiving DCC-3116 and trametinib combination: previous treatment&#xD;
             with trametinib that resulted in treatment discontinuation due to intolerability as a&#xD;
             result of an adverse event (AE) that was considered related to trametinib.&#xD;
&#xD;
         15. Known allergy or hypersensitivity to any component of the investigational drug&#xD;
             product.&#xD;
&#xD;
         16. Known human immunodeficiency virus or hepatitis C infection only if the participant is&#xD;
             taking medications that are excluded per protocol, active hepatitis B, or active&#xD;
             hepatitis C infection.&#xD;
&#xD;
         17. If female, the participant is pregnant or lactating.&#xD;
&#xD;
         18. Ongoing or prior participation in an investigational drug study within 30 days of&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Team</last_name>
    <role>Study Director</role>
    <affiliation>Deciphera Pharmaceuticals LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Team</last_name>
    <phone>833-432-2237</phone>
    <email>clinicaltrials@deciphera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin Weekes, MD, PhD</last_name>
      <phone>617-726-4000</phone>
      <email>cdweekes@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Deleon</last_name>
      <phone>210-307-0140</phone>
      <email>cdeleon@nextoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ly Nguyen</last_name>
      <phone>713-563-2169</phone>
      <email>LMNguyen1@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Deleon</last_name>
      <phone>210-307-0140</phone>
      <email>cdeleon@nextoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RAF</keyword>
  <keyword>RAS</keyword>
  <keyword>KRAS</keyword>
  <keyword>NRAS</keyword>
  <keyword>BRAF</keyword>
  <keyword>DCC-3116</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

